Methods of diagnosing infectious disease pathogens and their drug sensitivity

Patent metadata

Field	Value
Publication number	US-10982291-B2
Application number	US-201816035240-A
Country	US
Kind code	B2
Filing date	Jul 13, 2018
Priority date	Feb 24, 2010
Publication date	Apr 20, 2021
Grant date	Apr 20, 2021

Abstract

The specification relates generally to methods of detecting, diagnosing, and/or identifying pathogens, e.g., infectious disease pathogens and determining their drug sensitivity and appropriate methods of treatment. This invention also relates generally to methods of monitoring pathogen infection in individual subjects as well as larger populations of subjects.

First claim

What is claimed is:

1. A method of identifying a pathogen in a test sample, the method comprising:
obtaining or having obtained a test sample suspected of comprising a pathogen, wherein the test sample is a crude sample of a subject;
exposing or having exposed the test sample to one or more nucleic acid probes that bind specifically to one or more target nucleic acids that uniquely identifies a pathogen in the test sample, wherein the exposure occurs for less than one hour and wherein the one or more nucleic acid probes have a region of at least 20 nucleotides in length that is a perfect match to the pathogen but wherein said region does not match any other known organism at a level exceeding 50%;
determining or having determined the presence of the one or more target nucleic acids by imaging or counting reporter tags associated with the one or more nucleic acid probes, thereby identifying the presence of the pathogen in the test sample, and
administering to the subject a drug to which the identified pathogen is sensitive.

2. The method of claim 1 , wherein the one or more target nucleic acids is mRNA.

3. The method of claim 1 , wherein the reporter tag is a fluorescent tag.

4. The method of claim 1 , wherein a virus is identified, optionally wherein the virus is selected from the group consisting of a coronavirus, an influenza virus, a respiratory syncytial virus, a parainfluenza virus, an adenovirus, a rhinovirus, a metapneumovirus, a coxsackievirus, an echovirus, a hantavirus, a varicella zoster virus, a cytomegalovirus (cmv), a bk virus, a herpes virus, an enterovirus, a lymphocytic choriomeningitis virus, an eastern equine encephalitis virus, a western equine encephalitis virus, a Venezuelan equine encephalitis virus, a west nile virus, a St Louis encephalitis virus, a Murray valley encephalitis virus, a Japanese encephalitis virus, a dengue virus, a La crosse virus, a Rift valley fever virus, a Nipah virus, a Lassa fever virus, a rabies virus and an Epstein barr virus.

5. The method of claim 1 , further comprising treating the test sample under conditions that release nucleic acid from cells of the test sample.

6. The method of claim 1 , wherein one or more nucleic acid probes each binds to two or more different target nucleic acid sequences.

7. The method of claim 1 , further comprising exposing or having exposed the test sample to one or more drug of interest, prior to said step of exposing or having exposed the test sample to the one or more nucleic acid probes.

8. The method of claim 7 , wherein the drug of interest is selected from the group consisting of isoniazid, rifampin, ethambutol, streptomycin and a fluoroquinolone, optionally wherein the fluoroquinolone is selected from the group consisting of ciprofloxacin and moxifloxacin.

9. The method of claim 1 , wherein the test sample is partitioned into smaller sub-samples, optionally wherein the different sub-samples are exposed to either no drug or different, known or potential drugs.

10. The method of claim 1 , wherein the subject is human.

11. The method of claim 1 , wherein the pathogen is selected from the group consisting of a bacteria, a virus, and a fungus.

12. The method of claim 1 , wherein the crude sample comprises extracts of mechanically lysed cells or cells that are lysed mechanically, optionally wherein the cells are lysed via sonication, French press, electroporation or a microfluidic device comprising fabricated structures.

13. The method of claim 1 , wherein the method comprises use of a microfluidic device or a microarray.

14. The method of claim 1 , wherein the method further comprises exposing or having exposed the test sample to a reporter nucleic acid probe that is conjugated to a fluorescent tag, optionally wherein the tag is a bar code.

15. The method of claim 1 , wherein one or more of the nucleic acid probes is conjugated to a label, optionally wherein the label is selected from the group consisting of a fluorophore, biotin, digoxygenin, and a radioactive isotope.

16. The method of claim 1 , wherein the method is used to monitor and treat a pathogen infection.

17. The method of claim 1 , wherein the target nucleic acid is a target RNA, optionally wherein the target nucleic acid is a target mRNA.

18. The method of claim 1 , wherein the one or more target nucleic acids is conserved across the species of pathogen.

Assignees

• Broad Inst Inc
• Massachusetts Gen Hospital

Inventors

• Gomez James
• Hung Deborah
• Barczak Amy

Classifications

• C12Q1/6888 Primary

  for detection or identification of organisms · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2333/35

  from Mycobacteriaceae (F) · CPC title

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• C12Q1/6809

  Methods for determination or identification of nucleic acids involving differential detection · CPC title